Dianthus widens loss as interim CAPTIVATE data lifts clinical pipeline

Dianthus Therapeutics reported encouraging interim clinical data and continued pipeline progress alongside a wider second-quarter loss, highlighting the competing demands of advancing multiple investigational programmes.

The company said the first 40 participants to complete Part A of its Phase 3 CAPTIVATE trial in chronic inflammatory demyelinating polyneuropathy recorded a 75% response rate. That exceeded Dianthus’ 50% benchmark, but the analysis remains interim and covers only part of the cohort. Guidance on Part B is expected by the end of 2026.

Enrollment in the Phase 2 MoMeNtum trial for multifocal motor neuropathy finished at 46 patients, above the original target of 36. Dianthus expects top-line results in December. It also began the Phase 3 EMERGE trial in generalised myasthenia gravis in June, with top-line results not expected until the second half of 2028.

Dianthus’ second-quarter net loss increased to US$50.2 million from US$31.6 million a year earlier. Research and development expenses rose to US$48.7 million from US$26.3 million, while general and administrative costs reached US$13.6 million, compared with US$8.9 million.

The clinical-stage biotechnology company, which has no approved products, reported approximately US$1.2 billion in cash as at 30 June and said it could fund operations into 2030. It also disclosed DNTH312, a fusion protein combining claseprubart with TACI, with Phase 1 readiness targeted for the end of 2027.

The updates were reported by Yahoo Finance, which noted that claseprubart is being tested across several autoimmune indications. The clinical findings remain subject to further readouts and do not establish regulatory success.